Benzathine analogs

Patent metadata

Field	Value
Publication number	US-9359284-B2
Application number	US-201314406189-A
Country	US
Kind code	B2
Filing date	Mar 13, 2013
Priority date	Jun 8, 2012
Publication date	Jun 7, 2016
Grant date	Jun 7, 2016

Abstract

A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of:

wherein X is a divalent linking moiety; and
R 1 -R 10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R 3 or R 8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.

First claim

What is claimed is:

1. A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of formula II:

wherein X is an optionally-substituted alkanediyl,
R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 9 and R 10 are each individually hydrogen, alkyl, halogen, amino, or hydroxy, and R 3 and R 8 are each a 6-membered N-heterocycle.

2. The compound of claim 1 , wherein the 6-membered N-heterocycle is selected from pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, or triazinyl.

3. The compound of claim 1 , wherein X is an alkanediyl having a structure of —C n H 2n — wherein n is 2 to 5.

4. The compound of claim 3 , wherein X is —CH 2 —CH 2 —.

5. The compound of claim 1 , wherein the compound is selected from:

6. A pharmaceutical composition comprising at least one compound of claim 1 and at least one pharmaceutically acceptable additive.

7. A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of:

8. The compound of claim 1 , wherein the 6-membered N-heterocycle is pyrimidinyl.

9. The compound of claim 1 , wherein X is an alkanediyl having a structure of —C n H 2n — wherein n is 2 to 5, and the 6-membered N-heterocycle is pyrimidinyl.

10. A pharmaceutical composition comprising the compound of claim 7 and at least one pharmaceutically acceptable additive.

Assignees

• Univ Pittsburgh—Of The Commonwealth System Of Higher Education
• Us Dept Veterans Affairs
• Us Dept Veterans Affairs

Inventors

• Chen Beibei
• Mallampalli Rama K

Classifications

• A61K31/341

  not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine · CPC title

• C07D277/28

  Radicals substituted by nitrogen atoms · CPC title

• C07D239/26

  with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms · CPC title

• C07D207/06

  with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms · CPC title

• A61P19/00

  Drugs for skeletal disorders · CPC title